CMPS:NASDAQ
Compass Pathways PLC
US$ 8,44
arrow_downward
-5,06%(-0,45) 1D
US$ 8,53
arrow_upward
+1,07% (+0,090)bedtimeAfter-market
Fechado: 28 de abr., 16:00:01 GMT-4 · USD
search
Todos os símbolos
1D
5D
1M
6M
YTD
1A
5A
MÁX
| Códigos | Preço | Variação | % de variação |
|---|
insights_autoGerando os principais insights para CMPS…
Abrir
US$ 8,75
Alta
US$ 8,97
Baixa
US$ 8,39
Valor de mercado
1,14 bi
Volume médio
3,76 mi
Volume
3,13 mi
Alto — 52 sem
US$ 10,21
Baixo — 52 sem
US$ 2,25
LPA
-US$ 3,08
Beta
2,01
Ações em circulação
134,92 mi
Nº de funcionários
156
Notícias
De fontes em toda a Web
Insider Monkey
·
há 1 dia
FDA Grants Rolling Review and CNPV Designation to Compass Pathways (CMPS) for TRD Treatment
Perfil
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine.
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus.
Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use. Wikipedia
Sobre Compass Pathways PLC
O conteúdo gerado com IA pode ter erros. Saiba mais